Si Wentao, Kan Chen, Zhang Leisheng, Li Feifei
Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province and NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China.
Oncol Lett. 2023 Mar 15;25(5):176. doi: 10.3892/ol.2023.13762. eCollection 2023 May.
Breast cancer is the most common malignancy and ranks second among the causes of tumor-associated death in females. The recurrence and drug resistance of breast cancer are intractable due to the presence of breast cancer stem cells (BCSCs), which are adequate to initiate tumor formation and refractory to conventional remedies. Runt-related transcription factor 2 (RUNX2), a pivotal transcription factor in mammary gland and bone development, has also been related to metastatic cancer and BCSCs. State-of-the-art research has indicated the retention of RUNX2 expression in a more invasive subtype of breast cancer, and in particular, triple-negative breast cancer development and drug resistance are associated with estrogen receptor signaling pathways. The present review mainly focused on the latest updates on RUNX2 in BCSCs and their roles in breast cancer progression and drug resistance, providing insight that may aid the development of RUNX2-based diagnostics and treatments for breast cancer in clinical practice.
乳腺癌是最常见的恶性肿瘤，在女性肿瘤相关死亡原因中排名第二。由于乳腺癌干细胞（BCSCs）的存在，乳腺癌的复发和耐药性难以解决，这些干细胞足以引发肿瘤形成且对传统治疗方法具有抗性。 runt相关转录因子2（RUNX2）是乳腺和骨骼发育中的关键转录因子，也与转移性癌症和BCSCs有关。最新研究表明，RUNX2表达在侵袭性更强的乳腺癌亚型中得以保留，特别是三阴性乳腺癌的发展和耐药性与雌激素受体信号通路有关。本综述主要关注BCSCs中RUNX2的最新进展及其在乳腺癌进展和耐药性中的作用，为临床实践中基于RUNX2的乳腺癌诊断和治疗的发展提供可能有用的见解。
